Thrive Pharmacy Recalls Subpotent Buprenorphine Troches in Florida
Thrive Pharmacy is voluntarily recalling 71 Buprenorphine troches in Florida because the medication was found to be subpotent.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The FDA classified this recall as Class II. Per the rubric, FDA Class II recalls are assigned a severity score of 4 (Severe), particularly when involving significant health risks such as subpotent medication.
Plain-English summary
Thrive Pharmacy, operating as Matthew 7:25 Inc, is voluntarily recalling 71 units of Buprexone Banana cream 6-0.6 mg Troche. The product was distributed in Florida and is identified by Lot 190918B with an expiration date of 03/16/2020.
The recall was initiated because the medication was found to be subpotent, meaning it did not contain the full amount of the active ingredient as labeled. The FDA classified this recall as Class II, indicating a situation where use of the product could cause temporary or medically reversible health consequences.
Consumers who have this specific lot of Buprenorphine troches should stop using them and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- Buprexone Banana cream 6-0.6 mg Troche, supplied in plastic troche molds with cardboard outer sleeve, Thrive Pharmacy 2863 St Johns Bluff RD. South # 135 Jacksonville, Florida
- Manufacturer
- Matthew 7:25 Inc dba Thrive Pharmacy
- Category
- Drug — Pharmaceutical
- Hazard
- Affected units
- 71
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 190918B Exp. 03/16/2020
Distribution
Distributed in 1 state:
Part of a larger recall action
This product is one of 3 recalled by Matthew 7:25 Inc dba Thrive Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 3 products in this recall →Related recalls
Same manufacturer · Matthew 7:25 Inc dba Thrive Pharmacy
See all →- SevereThrive Pharmacy Recalls Subpotent Buprenorphine Troches in Florida
FDA (Drugs) · 2020-04-01
- SevereThrive Pharmacy Recalls Subpotent Buprenorphine Troches in Florida
FDA (Drugs) · 2020-04-01
Same hazard · subpotent drug
See all →- LowImprimisRx Recalls Subpotent Povidone Iodine and Proparacaine Ophthalmic Solution
FDA (Drugs) · 2026-09-16
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
Similar recalls
- SevereTris Pharma Recalls Superpotent Infant Ibuprofen Suspension
FDA (Drugs) · 2019-02-20
- SevereTeva Recalls Buprenorphine and Naloxone Sublingual Tablets Due to Impurities
FDA (Drugs) · 2017-03-22
- SevereAlvogen Buprenorphine and Naloxone Sublingual Film recalled for subpotent active ingredients
FDA (Drugs) · 2021-07-14
- LowNorepinephrine Bitartrate IV Bags Recalled for Subpotency
FDA (Drugs) · 2022-03-02
- ModerateTestosterone Cream Recalled for Lack of Processing Control
FDA (Drugs) · 2020-04-22
- ModerateTeva Recalls Buprenorphine Transdermal Patches for Stability Failures
FDA (Drugs) · 2020-10-07